Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

2.53
-0.1400-5.24%
Post-market: 2.570.0399+1.58%19:21 EDT
Volume:4.16M
Turnover:10.47M
Market Cap:392.45M
PE:-3.91
High:2.70
Open:2.69
Low:2.44
Close:2.67
Loading ...

BUZZ-Humacyte tumbles on planned equity raise

Reuters
·
26 Mar

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire
·
26 Mar

Humacyte Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
21 Mar

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

GlobeNewswire
·
10 Mar

Humacyte Partners With Trestle Biotherapeutics on Bioengineered Kidney Research

MT Newswires Live
·
06 Mar

Humacyte, Trestle Biotherapeutics announce research collaboration

TIPRANKS
·
06 Mar

Trestle Bio Announces Research Collaboration with Humacyte

Business Wire
·
06 Mar

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

GlobeNewswire
·
03 Mar

Humacyte Shares Rise After Receiving US Patent for Bioreactor Manufacturing System

MT Newswires Live
·
28 Feb

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

GlobeNewswire
·
27 Feb

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Feb

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

GlobeNewswire
·
26 Feb

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Simply Wall St.
·
19 Feb

Humacyte, Pluristyx Announce Gene Editing Partnership

MT Newswires Live
·
29 Jan

Humacyte, Pluristyx announce expanded partnership

TIPRANKS
·
28 Jan

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

GlobeNewswire
·
28 Jan